Gilead Trodelvy+Keytruda CHMP: 35% TNBC Risk Cut, ASCENT-04

Gilead Sciences (GILD) announced today that the European Medicines Agency’s CHMP adopted a positive opinion recommending approval of Trodelvy plus Keytruda for first-line treatment of PD-L1 positive metastatic triple-negative breast cancer. The combination reduced the risk of disease progression or death by 35% versus Keytruda alone in the Phase 3 ASCENT-04 trial.

The numbers

• Ticker: GILD
• Stock price: $130.86 (close July 23, 2026)
• Market cap: $162.5 billion
• Drug: Trodelvy (sacituzumab govitecan), a TROP2-directed antibody-drug conjugate (ADC)
• Combination: Trodelvy plus Keytruda (pembrolizumab, Merck’s PD-1 inhibitor)
• Indication: First-line PD-L1 positive metastatic triple-negative breast cancer (TNBC)
• Risk reduction: 35% reduction in disease progression or death vs. Keytruda alone (ASCENT-04)

The CHMP also recommended Trodelvy as a monotherapy for first-line TNBC patients who are not candidates for PD-1/PD-L1 inhibitors, based on the ASCENT-03 trial showing a 38% risk reduction versus chemotherapy. Together, these two opinions would cover the full first-line TNBC population across PD-L1 status.

What this means

Trodelvy is an antibody-drug conjugate: it links a tumor-targeting antibody to a chemotherapy payload, delivering the chemo directly to cancer cells expressing TROP2, a protein found on most breast cancers. The ADC plus checkpoint inhibitor combination attacks the tumor from two angles: the ADC delivers targeted cell killing while the checkpoint inhibitor releases the immune system’s brakes on T-cells.

Triple-negative breast cancer accounts for about 10-15% of breast cancers and has the worst prognosis among breast cancer subtypes. The five-year survival rate for metastatic TNBC is approximately 12%, compared with 28% for other metastatic breast cancers. Few treatment options exist in the first-line setting beyond chemotherapy and Keytruda.

The FDA already approved Trodelvy for first-line TNBC in June 2026. The CHMP positive opinion paves the way for European Commission approval, which typically follows CHMP recommendations within 67 days. The same CHMP meeting produced a positive opinion for Shionogi’s Zokovea, the first oral antiviral recommended for COVID-19 post-exposure prophylaxis in the EU. This expands Trodelvy’s revenue base beyond the US.

Context

Gilead acquired Trodelvy through its $21 billion Immunomedics acquisition in 2020, a deal widely criticized at the time for its price tag. The drug underperformed commercial expectations for years. The first-line TNBC approval in June 2026 and now the EU expansion mark a turning point. Gilead’s oncology franchise is building momentum, though HIV remains the company’s primary revenue driver with Q2 earnings expected August 4.

What to watch

The risk: Gilead faces a Leerink downgrade to Market Perform with a $127 price target, roughly 3% below the current price. Analysts question whether Trodelvy’s momentum justifies a higher multiple when the HIV franchise faces increasing competition from Gilead’s own lenacapavir and Merck’s pipeline. Watch the August 4 earnings call for management’s Trodelvy sales guidance and any update on the ASCENT-04 full data presentation at a medical meeting.

Sources: Gilead CHMP announcement, Finnhub coverage via Yahoo, FDA first-line TNBC approval context, Gilead lenacapavir HIV PrEP coverage

What It Means for the Trade

This is a slow-motion redemption trade finally paying out. Trodelvy was the $21 billion Immunomedics bet that underperformed for years, and 2026 has delivered the two things that change the story: a US first-line TNBC approval in June and now full first-line EU coverage across both PD-L1-positive (with Keytruda) and PD-L1-negative or IO-ineligible (monotherapy, from ASCENT-03) populations. The 35% progression-risk reduction against Keytruda alone in ASCENT-04 is the kind of number that changes guideline positioning, not just labels — combinations that beat the standard backbone get written into sequencing.

The trade cadence from here: European Commission approval within ~67 days (near-automatic after CHMP), then the August 4 earnings call where management’s Trodelvy guidance either confirms or tempers the first-line ramp. The Leerink downgrade to $127 frames the bear case cleanly: Trodelvy momentum is real, but the HIV franchise — the actual revenue engine — faces its own competitive clock. GILD at $130.86 is pricing both.

Mechanism and Market Context

The biology of the combination is the reason the data holds. Sacituzumab govitecan is a TROP2-directed ADC carrying a topoisomerase-I payload — targeted cell killing with bystander effect; pembrolizumab releases PD-1 braking on T cells. Immunogenic cell death from the ADC’s payload plausibly feeds antigen release that the checkpoint inhibitor amplifies — the mechanistic logic behind ADC-plus-IO combinations across oncology. A 35% risk reduction on top of Keytruda alone in PD-L1-positive disease is the clinical expression of that synergy.

The competitive context: metastatic TNBC has a five-year survival around 12%, and the first-line options beyond chemo plus Keytruda were thin. Trodelvy now owns the post-IO-progression space (from ASCENT) and has first-line claims on both sides of PD-L1 status — a positioning breadth no rival ADC has in this indication yet, though the TROP2 field (Datroway, sac-TMT programs) is crowding fast.

Risks and What Could Go Wrong

1. Commercial conversion lag. Positive CHMP opinions do not write prescriptions; if European uptake of the first-line combination is slow (as US launch curves have been), the multiple re-rates back down.
2. ADC competition. TROP2 ADCs from Daiichi Sanyo/AstraZeneca are advancing in breast cancer; a cleaner-tolerability rival could displace Trodelvy’s position within its own indication.
3. HIV overhang. The stock’s driver is lenacapavir transition and PrEP; any HIV stumbles make Trodelvy strength irrelevant to the multiple.
4. Guideline gatekeeping. If ESMO or NCCN sequencing is cautious about ADC-plus-IO first-line, the label win does not convert to share.

Net: a real franchise inflection arriving on schedule. The trade is the August 4 call; position ahead of it only with the HIV question sized honestly.